ArticleOdontology2026
Hypoglycemic and tissue protective effects of mangosteen (Garcinia mangostana L.) on diabetes associated periodontal tissue alterations.
Article in Odontology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current research aimed to evaluate the effects of mangosteen (Garcinia mangostana L.) on serum glucose levels and periodontal ligament (PDL) architecture in hyperglycemic diabetic rat models, with particular focus on PDL collagen integrity and alveolar bone status. A total of forty-eight male Dawley rats (150-200 g, 3-6 months) were randomly allocated into three equal groups (n = 16): control, diseased diabetic (DM), and mangosteen (MG) treated diabetic (DM-MG) groups. Diabetes was induced in both DM and DM-MG groups employing streptozotocin (STZ), with only DM-MG group undergoing MG treatment. Serum glucose and body weight recorded weekly for 35 days. All euthanized rats were subjected for histological assessment utilizing hematoxylin and eosin stain, and morphometric evaluation of collagen integrity using Masson's trichrome stain. RUNX-2, a transcription factor associated with osteogenic differentiation was assessed by immunohistochemistry and ELISA to evaluate osteogenic activity and alveolar bone status. Control group reported consistent weight gain, but DM group experienced considerable weight loss and increased serum glucose levels. DM-MG group showed substantial improvements in both metrics. Histologically, DM group revealed signs of PDL structural disruption, whilst DM-MG group displayed partial improvement in PDL organization and attenuation of diabetes-induced structural alterations. Collagen density and RUNX-2 activity were considerably higher in DM-MG group versus DM group. Statistical analysis demonstrated significant differences among the studied groups, DM-MG group showed significantly higher collagen area % and RUNX-2 expression compared to the DM group (Tukey: p ≤ 0.05 for collagen, p ≤ 0.001 for RUNX-2 IHC and ELISA), alongside improvement in body weight and serum glucose levels over the 35-day period (Two-way RM-ANOVA: p ≤ 0.001). MG exhibited notable hypoglycemic and partially attenuated diabetes-associated PDL tissue alterations, indicating its potentiality as a natural adjunctive therapeutic agent for managing diabetes and its associated periodontal alterations.
Indexed as
Identifiers
42624971What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.